Antibody against CXCL12 and composition for treating hair loss containing the same
Antibodies targeting CXCL12 are developed to inhibit its activity, promoting hair growth and treating hair loss conditions with improved efficacy and reduced side effects compared to existing treatments.
Patent Information
- Application Number
- JP2024538090
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-27
- Filing Date
- 2022-12-23
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-12-23
AI Technical Summary
Current hair loss treatments, such as finasteride, dutasteride, minoxidil, and hair transplantation, come with significant side effects and limitations, while existing chemokine-based therapies are not specifically targeted for hair growth promotion.
Development of antibodies, specifically neutralizing and humanized antibodies against CXCL12, which inhibit CXCL12 activity to promote hair follicle growth and treat various forms of hair loss.
The antibodies effectively suppress CXCL12, leading to enhanced hair growth and improved treatment outcomes for conditions like alopecia areata, hereditary androgenic alopecia, and other forms of hair loss, with minimal side effects.
Smart Images

Figure 2024545321000004 
Figure 2024545321000005 
Figure 2024545321000006
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel antibody against CXCL12 and a composition for treating hair loss comprising the same. Specifically, the present invention relates to a neutralizing antibody or a humanized antibody against CXCL12, which has the effect of promoting hair growth by suppressing CXCL12. [Background technology]
[0002] Mouse hair grows, is maintained and falls out through a three-phase cycle: anagen, catagen and telogen. In general, apoptosis of hair follicle cells occurs 10-14 days after the anagen phase, and the hair goes through the catagen phase, in which the hair follicle shrinks, and the telogen phase, in which the hair prepares for the next anagen phase, which lasts an average of three months, before falling out. The reason that hair length differs depending on the area is that the duration of the anagen phase, which is a unique characteristic of the hair follicle, differs depending on the area.
[0003] Human hair also has a certain hair growth cycle, so a certain number of hairs are always maintained. However, as hair loss progresses, the hair papilla present in the hair root becomes smaller, and as the hair papilla becomes smaller, the thickness of the hair becomes thinner, and at the same time, the hair growth cycle becomes shorter. Therefore, as hair loss progresses, the hair becomes very thin and the hair growth cycle becomes even shorter, so that it falls out after a little growth.
[0004] Hair loss is known to be caused by a combination of factors including genetic causes, the effects of male hormones, endocrine disorders, nutritional deficiencies, drug use, childbirth, fever, and severe physical and mental stress such as surgery. Recently, the number of women experiencing hair loss has been increasing, not only due to male pattern hair loss, but also due to changes in diet and increased stress from the social environment, and the age of women experiencing hair loss is also decreasing.
[0005] Currently, the most commonly used hair loss treatments in Korea include finasteride (trade name Propecia®), dutasteride (trade name Avodart®), and minoxidil (trade name Minoxil® or Rogaine®). Finasteride and dutasteride are 5α-reductase inhibitors that inhibit the conversion of male hormone (testosterone) to 5α-dihydrotestosterone (DHT). However, these products cause side effects such as decreased libido, erectile dysfunction, and loss of driving and performance abilities. Meanwhile, minoxidil, although its mechanism has not yet been fully elucidated, is a potassium channel opener that hyperpolarizes cell membranes, and is thought to increase the supply of oxygen, blood, nutrients, etc. to hair follicles by vasodilation and potassium channel opening, thereby making hair follicles healthier. However, this product also causes side effects such as itching, erythema, skin irritation, and eye irritation at the application site, and unwanted hair growth has also been observed on other body parts besides the head. In recent years, hair transplantation has been attempted for patients with severe hair loss, but limitations due to high costs and side effects after the procedure have been pointed out.
[0006] On the other hand, chemokines are leukocyte chemotactic factors that attract leukocytes to various tissues of the body, a process that is essential in all bodily responses to inflammation and infection. Chemokines and their receptors are not only central to immune regulation and the pathophysiology of inflammatory and infectious diseases, but in recent years, specific roles have been shown in specific diseases, including autoimmune diseases, depending on the type of chemokine and its receptor, and therapeutic approaches have been proposed that regulate the activity of specific chemokines or their receptors.
[0007] Therefore, the inventors made efforts to develop a novel hair loss treatment agent and found that treatment with an antibody against CXCL12, a type of chemokine, promotes the growth of hair follicles and hair, thereby completing the present invention. [Prior art documents] [Non-patent literature]
[0008] [Non-Patent Document 1] Tran PB et al., Chemokine receptors in the brain: a developing story.J.Comp.Neurol.2003;457:1-6. [Non-Patent Document 2] Zou YR et al.,Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.Nature.1998;393:595-599. [Non-Patent Document 3] Michel et al.Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways.British journal of dermatology.2017;177:1322-1336. Summary of the Invention [Problem to be solved by the invention]
[0009] An object of the present invention is to provide an antibody against CXCL12.
[0010] An object of the present invention is to provide a composition for preventing or treating hair loss, which comprises an antibody against CXCL12. [Means for solving the problem]
[0011] The present invention provides an antibody that specifically binds to CXCL12, a pharmaceutical composition for preventing or treating hair loss comprising an antibody that specifically binds to CXCL12, as well as a polynucleotide encoding an antibody that specifically binds to CXCL12 and a vector comprising the same.
[0012] The antibody comprises a heavy chain variable region comprising a CDRH1 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:3; a CDRL1 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:5, and a CDRH3 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:6. The antibody may be a monoclonal antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising CDRH1 having the amino acid sequence of SEQ ID NO:1, CDRH2 having the amino acid sequence of SEQ ID NO:2, and CDRH3 having the amino acid sequence of SEQ ID NO:3, and a light chain variable region comprising CDRL1 having the amino acid sequence of SEQ ID NO:4, CDRL2 having the amino acid sequence of SEQ ID NO:5, and CDRL3 having the amino acid sequence of SEQ ID NO:6. ...
[0013] The antibody comprises a heavy chain variable region comprising: a CDRH1 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:1; a CDRH2 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:2; and a CDRH3 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:3; a CDRL1 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:4; a CDRL2 having a sequence that has at least 90%, 95% or 99% sequence identity to the amino acid sequence of SEQ ID NO:5; and a light chain variable region comprising CDRH1 having the amino acid sequence of SEQ ID NO: 1, CDRH2 having the amino acid sequence of SEQ ID NO: 2, and CDRH3 having the amino acid sequence of SEQ ID NO: 3, and a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising CDRH1 having the amino acid sequence of SEQ ID NO: 1, CDRH2 having the amino acid sequence of SEQ ID NO: 2, and CDRH3 having the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising CDRL1 having the amino acid sequence of SEQ ID NO: 4, CDRL2 having the amino acid sequence of SEQ ID NO: 5, and CDRL3 having the amino acid sequence of SEQ ID NO: 6.
[0014] The antibody may be a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising a sequence having at least 90%, 95% or 99% sequence homology to any of the amino acid sequences of SEQ ID NO:7 to SEQ ID NO:9, and a light chain variable region comprising a sequence having at least 90%, 95% or 99% sequence homology to any of the amino acid sequences of SEQ ID NO:10 to SEQ ID NO:12, and is preferably a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising any of the amino acid sequences of SEQ ID NO:7 to SEQ ID NO:9, and a light chain variable region comprising any of the amino acid sequences of SEQ ID NO:10 to SEQ ID NO:12.
[0015] The antibody may be a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10, or a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11, or a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
[0016] The antibody may be a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10, or a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11, or a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
[0017] The antibody may be a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10, or a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11, or a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
[0018] The hair loss may be alopecia areata, hereditary androgenic alopecia, telogen effluvium, traumatic alopecia, trichotillomania, pressure-induced alopecia, anagen effluvium, pityriasis alopecia, syphilitic alopecia, seborrheic alopecia, symptomatic alopecia, cicatricial alopecia, congenital alopecia, or hair loss caused by side effects of drugs.The hair loss caused by side effects of drugs may also be hair loss caused by anticancer drugs, anticoagulants, antidepressants, or hormonal drugs, and the anticancer drugs may be anticancer drugs for the treatment of cancers selected from the group consisting of melanoma, epithelial cancer, breast cancer, cervical cancer, solid cancer, urothelial cell carcinoma, non-small cell lung cancer, pancreatic adenocarcinoma, renal cancer, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer, and gastrointestinal cancer.
[0019] The present invention provides a composition for preventing or treating hair loss, comprising an antibody that specifically binds to CXCL12.
[0020] The present invention provides use of a composition comprising an antibody that specifically binds to CXCL12 for the prevention or treatment of hair loss.
[0021] The present invention provides a method of treating hair loss by administering to a subject suffering from hair loss an antibody that specifically binds to CXCL12. Effect of the Invention
[0022] The present invention relates to a novel antibody against CXCL12 and a composition for treating hair loss containing the same. Since the antibody against CXCL12 has the effect of suppressing CXCL12 and promoting hair growth, the composition is useful for preventing or treating hair loss. [Brief description of the drawings]
[0023] [Figure 1] FIG. 1 shows the results of hair follicle growth by treatment with a neutralizing antibody against CXCL12 of the present invention in a human hair follicle culture model. [Diagram 2] FIG. 1 shows the results of hair follicle growth by treatment with a neutralizing antibody against CXCL12 of the present invention in a human hair follicle culture model. [Diagram 3]FIG. 1 shows the results of hair growth by treatment with a neutralizing antibody against CXCL12 of the present invention in a mouse anagen induction model. [Figure 4] FIG. 1 shows the results of hair growth by treatment with a neutralizing antibody against CXCL12 of the present invention in a mouse anagen induction model. [Diagram 5] FIG. 1 shows the results of analyzing the antigen-binding affinity of the humanized antibody of the present invention against CXCL12. [Figure 6] FIG. 1 shows the results of hair follicle growth by treatment with the humanized antibody against CXCL12 of the present invention in a mouse whisker culture model. [Figure 7] FIG. 1 shows the results of hair follicle growth by treatment with the humanized antibody against CXCL12 of the present invention in a mouse whisker culture model. [Figure 8] FIG. 1 shows the results of hair growth by treatment with the humanized antibody against CXCL12 of the present invention in a mouse anagen induction model. [Figure 9] FIG. 1 shows the results of hair growth by treatment with the humanized antibody against CXCL12 of the present invention in a mouse anagen induction model. [Figure 10] FIG. 1 shows the results of hair growth by treatment with the humanized antibody against CXCL12 of the present invention in an animal model of alopecia areata. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to the accompanying drawings, in which: FIG. 1 is a block diagram of a semiconductor device according to an embodiment of the present invention;
[0025] Throughout this specification, when a part is said to "comprise" a certain element, this does not mean that it excludes other elements, but that it may further include other elements, unless otherwise specified.
[0026] The present invention relates to a neutralizing antibody or a humanized antibody against CXCL12, and a composition for treating hair loss comprising an antibody against CXCL12.
[0027] The neutralizing antibody against CXCL12 may be a monoclonal antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising CDRH1 having the amino acid sequence of SEQ ID NO: 1, CDRH2 having the amino acid sequence of SEQ ID NO: 2, and CDRH3 having the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising CDRL1 having the amino acid sequence of SEQ ID NO: 4, CDRL2 having the amino acid sequence of SEQ ID NO: 5, and CDRL3 having the amino acid sequence of SEQ ID NO: 6; it may be a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising CDRH1 having the amino acid sequence of SEQ ID NO: 1, CDRH2 having the amino acid sequence of SEQ ID NO: 2, and CDRH3 having the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising CDRL1 having the amino acid sequence of SEQ ID NO: 4, CDRL2 having the amino acid sequence of SEQ ID NO: 5, and CDRL3 having the amino acid sequence of SEQ ID NO: 6; or it may be a humanized antibody that specifically binds to CXCL12, comprising a heavy chain variable region comprising any of the amino acid sequences of SEQ ID NOs: 7 to 9, and a light chain variable region comprising any of the amino acid sequences of SEQ ID NOs: 10 to 12.
[0028] In the present invention, "CXCL12 (CXC motif chemokine 12)" refers to stromal cell-derived factor 1 (SDF1), a type of chemokine, which is known to interact with CXCR4 as a ligand for the CXC chemokine receptor CXCR4 and has also been reported as a ligand for CXCR7 (RDCI). CXCL12 is widely expressed in various tissue types, including the heart, liver, spleen, kidney, brain, skeletal muscle, endothelial cells, epithelial tissues, and stem cells.
[0029] In the present invention, "chemokine" refers to a basic, heparin-binding low molecular weight protein that has leukocyte migration and activation activity. Chemokine molecules contain four cysteine residues, and are classified into four subfamilies, CXC (CXCL), CC (CCL), CX3C (CX3CL), and C (XCL), depending on the arrangement of the cysteine residues in the first two molecules. At present, at least 40 species have been identified.
[0030] In the present invention, a "neutralizing antibody" means an antibody that specifically binds to an antigen, whether in particulate or molecular form, and eliminates or reduces the activity of the antigen when the antigen has biological activity such as infectiousness, toxicity, or enzymatic activity in a living body.
[0031] In the present invention, a "humanized antibody" refers to an antibody having an amino acid sequence corresponding to that of an antibody produced by a human and / or an antibody produced by the human antibody production techniques disclosed in the present invention.
[0032] The term "antibody" refers to a natural immunoglobulin or a partially or wholly synthetically produced immunoglobulin. The term also includes any polypeptide or protein that contains an antigen-binding domain of an antibody. Antibody fragments that contain an antigen-binding domain are molecules such as Fab, scFv, Fv, dAb, Fd, and diabody. The term "antibody" is used in a broad sense, specifically including complete monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies) formed from at least two complete antibodies, and also antibody fragments that exhibit the desired biological activity. An antibody is composed of two heavy chains and two light chains, and has a variable region whose amino acid sequence changes depending on the type of target antigen, and a constant region whose sequence does not change.
[0033] The light and heavy chain variable regions contain three highly variable regions called "complementarity-determining regions (CDRs)". CDRs bind to an epitope of an antigen, and the CDRs of each chain typically have three regions (CDR1, CDR2, and CDR3).
[0034] As used herein, the term "specifically bind" is well known to those skilled in the art, and specifically means that an antigen and an antibody specifically interact with each other to form an antigen-antibody complex and induce an immunological reaction.
[0035] In the present invention, "hair loss" refers to a state in which hair is not present in areas where hair should normally be present, regardless of the cause, and includes, but is not limited to, alopecia areata, hereditary androgenic alopecia, telogen effluvium, traumatic alopecia, trichotillomania, pressure effluvium, anagen effluvium, pityriasis alopecia, syphilitic alopecia, seborrheic alopecia, symptomatic alopecia, cicatricial alopecia, congenital alopecia, or hair loss due to drug side effects.
[0036] In the present invention, "prevention" means any action of suppressing or delaying the onset of a disease by administering a composition, and "treatment" means any action of improving or beneficially changing the symptoms of an individual who has developed a disease or an individual who is suspected of having a disease by administering a composition.
[0037] The pharmaceutical compositions of the present invention may be formulated in any form suitable for use, including oral dosage forms such as powders, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, and aerosols, topical skin preparations such as ointments and creams, suppositories, injections, fillers, and sterile injection solutions, by conventional methods.
[0038] The present invention will be described in more detail below with reference to examples. However, these examples are merely for explaining the present invention and are not intended to limit the present invention. EXAMPLES
[0039] Generation of neutralizing antibodies against CXCL12 1-1. Preparation of immunized mice An emulsion was prepared by mixing 50 μg (per mouse) of recombinant human CXCL12 protein (cat#13511-HNCE) purchased from sinobiologics with the same volume of Freund's complete adjuvant (Sigma, USA). The emulsion thus prepared was injected intraperitoneally into six 7-week-old female BALB / C mice. 50 μg of antigen was injected into each mouse in a total volume of 500 μL. After 1 week and 2 weeks, emulsions of antigen mixed with incomplete Freund's adjuvant (Sigma, USA) were further injected intraperitoneally into the mice.
[0040] 1-2. Confirmation of antibody production Blood was collected from the eyeballs of mice immunized by the above method, placed in a 1.5 mL microcentrifuge tube, and then centrifuged at 13,000 rpm for 10 minutes. Serum was separated and stored at -20°C until an experiment to confirm antibody production was performed. Antibody production was confirmed by enzyme immunoassay using the antigen protein, and then an emulsion of incomplete Freund's adjuvant (Sigma, USA) and the antigen was injected into the abdominal cavity of the mice again 3 days before cell fusion.
[0041] 1-3. Generation of hybridomas Antibody production was confirmed, and then the mice were sacrificed. Spleen cells were isolated and fused with myeloma cells P3X63Ag8.653 (ATCC CRL-1580) to produce hybridomas. Specifically, mouse P3X63Ag8.653 cells were cultured in a culture plate using RPMI1640 medium supplemented with 10% fetal bovine serum. To perform cell fusion, P3X63Ag8.653 cells were washed twice with serum-free RPMI1640 medium (Hyclone, USA) and diluted to 1 × 10 7The cell concentration was adjusted to 100%. Mice were sacrificed by cervical dislocation to collect the spleens, which were then placed in a mesh container (Sigma, USA) for cell separation. A suspension of spleen cells was prepared, and the suspension was then washed by centrifugation. The spleen cell solution was exposed to Tris-NH4Cl (TRIS 20.6 g / L, NH4Cl 8.3 g / L) to lyse red blood cells. Completely separated antibody-producing cells were centrifuged at 400 × g for 5 min. They were then washed twice with serum-free medium and resuspended in 10 mL of medium. Lymphocytes were counted using a hemocytometer, and lymphocytes were found to be 1 × 10 8 was mixed with 1x10 P3X63Ag8.653 cells (10:1) in serum-free medium. After centrifugation at 400xg for 5 min, 1mL of the solution was added dropwise and mixed for 1 min using 50% (M / V) polyethylene glycol 1500 (Sigma, USA) warmed to 37°C. The fusion mixture thus prepared was diluted with serum-free RPMI1640 and centrifuged at 400xg for 3 min. The cells were suspended in 35mL of RPMI1640 selection medium supplemented with 20% fetal bovine serum and HAT (100μM hypoxanthine, 0.4μM aminopterin, 16μM thymidine). 100μL of the suspension was loaded onto a 96-well plate coated with feeder cells (macrophages isolated from the peritoneal cavity using RPMI1640) one day before and cultured at 37°C and 5% CO2. From 5 days later, the HAT medium was replaced every 2-3 days and the cells were cultured for 14 days. After 14 days, the medium was replaced with RPMI1640 medium supplemented with 20% fetal bovine serum and HT (medium obtained by removing 0.4 μM aminopterin from HAT) for secondary culture.
[0042] 1-4. Selection and separation of antibody-producing fused cells The supernatant of the culture medium of the fusion cells prepared as described above was collected, and the presence or absence of specific antibody production against the antigen prepared as described above was confirmed by enzyme immunoassay. The culture medium of the fusion cells showing an appropriate concentration of 4 times or more compared to the negative control group was selected, transferred to a 24-well plate and cultured. Furthermore, the cells were diluted (limiting dilution) so that one cell was placed per well in a 96-well plate and cultured, and then the culture medium was collected, and the CXCL12 protein used as an antigen was coated on the 96-well plate so that the amount was 0.1 μg per well. Then, the fusion cells that finally produced monoclonal antibodies were selected by enzyme immunoassay.
[0043] 1-5. Analysis of monoclonal antibodies The neutralizing antibody against CXCL12 obtained in the above process was named 2B12. As a result of sequence analysis, it was confirmed that the antibody comprises a heavy chain variable region including CDRH1 having the sequence of SEQ ID NO: 1, CDRH2 having the sequence of SEQ ID NO: 2, and CDRH3 having the sequence of SEQ ID NO: 3, and a light chain variable region including CDRL1 having the sequence of SEQ ID NO: 4, CDRL2 having the sequence of SEQ ID NO: 5, and CDRL3 having the sequence of SEQ ID NO: 6, as shown in Table 1.
[0044] [Table 1] EXAMPLES
[0045] Confirmation of the hair follicle growth-promoting effect of treatment with a neutralizing antibody against CXCL12 in a human hair follicle culture model The hair follicle growth-promoting effect of the neutralizing antibody against CXCL12 prepared in Example 1 was confirmed as follows.
[0046] Hair follicles from a man in his 30s were prepared and cultured as organs. The hair follicles were cultured in a 48-well plate with one per well, and divided into six groups: a negative control group, a positive control group (commercial antibody 50ng / mL, 500ng / mL), and a 2B12 treatment group (0.05ng / mL, 0.5ng / mL, 5ng / mL). The human hair follicles were then treated with each group and cultured in an incubator for four days.
[0047] As shown in Figures 1 and 2, the results of the human hair follicle culture experiment confirmed that treatment with the neutralizing antibody 2B12 against CXCL12 of the present invention promoted hair follicle growth, at a level equivalent to or superior to that of the positive control group.
[0048] Therefore, it is clear that the neutralizing antibody against CXCL12 of the present invention promotes the growth of hair follicles by suppressing CXCL12, and has an excellent hair growth effect. EXAMPLES
[0049] Confirmation of hair growth promotion effect by treatment with neutralizing antibody against CXCL12 in mouse anagen induction model The hair growth promoting effect of the neutralizing antibody against CXCL12 prepared in Example 1 was confirmed as follows.
[0050] The hair of 17 male C3H / HeN mice aged 7 weeks was shortened by a hair removal machine, the remaining hair was completely removed by a hair remover, and then the mice were allowed to acclimate for one day before use in the experiment. The mice were divided into groups of 5 to 6 mice each for the experiment. The mice were divided into 4 groups: a negative control group (IgG1, 5 μg / head), a positive control group (commercial antibody 5 μg / head), and a 2B12 antibody administration group (5 μg / head), and each group was subcutaneously injected into the back of the mice a total of 4 times at 4-day intervals (total dose 20 μg / head). The degree of hair growth on the back of the mice was followed up for 17 days after injection of each antibody. After 17 days, the backs of the mice with hair growth were shaved with a razor, and the weight of the resulting hair was measured.
[0051] As shown in Figures 3 and 4, the hair growth promoting effect in mice was evaluated, and it was confirmed that administration of the neutralizing antibody against CXCL12 of the present invention, 2B12, promoted hair growth.
[0052] Therefore, it is clear that the neutralizing antibody against CXCL12 of the present invention promotes hair growth by suppressing CXCL12, and has an excellent hair growth effect. EXAMPLES
[0053] Generation of humanized antibodies based on neutralizing antibodies against CXCL12 4-1. Generation of humanized antibodies To prepare a humanized antibody by modifying the neutralizing antibody against CXCL12 in Example 1 to have a structure corresponding to that of a human, a CDR grafting method was used to transplant the CDR of a mouse antibody onto a human antibody. The results of analysis of the sequences of the prepared humanized antibodies are shown in Table 2.
[0054] [Table 2]
[0055] 4-2. Construction and production of humanized IgG To construct a humanized IgG antibody, DNA sequences encoding the heavy and light chains of chimeric and humanized antibodies were synthesized and inserted into the pcDNA3.4 vector to construct an expression plasmid for full-length hIgG. The heavy and light chain plasmids were transfected according to the standard operating procedures (SOPs) of GenScriptProbio, and antibody expression was performed in Expi293F cell culture. As shown in Table 3, a total of nine combinations of humanized antibodies against the heavy and light chain variable regions were expressed.
[0056] [Table 3]
[0057] 4-3. Confirmation of antigen-binding affinity of purified humanized IgG (ELISA) The antigen-binding affinities of the nine combinations of humanized antibodies were confirmed as follows.
[0058] The initial concentration of all antibodies was 100 μg / mL, and they were serially diluted by 1 / 3 to 100 μL per well in a well plate, and incubated O / N at 4 °C. The next day, they were incubated with 3% Nonfat Milk at 37 °C for 1 hour. The plate was then washed with washing buffer, and then incubated with 100 μL of antigen (SDF-1α) at a concentration of 2 μg / mL for 2 hours at room temperature. After 2 hours, the well plate was washed with washing buffer, and then secondary antibody (0.1 μg / mL His-[HRP]) was added and treated for 45 minutes. Then, 100 μL of TMB-substrate was added to the washed well plate and reacted for 10 minutes, and then 50 μL of 1M HCL was added to stop the reaction. The absorbance was measured at 450 nm using a spectrophotometer to analyze the binding affinity.
[0059] As shown in FIG. 5, the antigen-binding affinity analysis confirmed that the nine combinations of humanized antibodies had excellent antigen-binding affinity, and in particular, four of the humanized antibodies had superior antigen-binding affinity to chimeric antibodies. EXAMPLES
[0060] Confirmation of the hair follicle growth-promoting effect of humanized antibody against CXCL12 in a mouse whisker model The hair follicle growth-promoting effect of the humanized antibody against CXCL12 prepared in Example 4 was confirmed as follows.
[0061] Terminal hair from female C57BL / 6 mice was trimmed and cultured in an organ culture. Hair follicles were cultured in a 48-well plate with one per well, and divided into 21 groups in total: a negative control group, a chimeric antibody treatment group (50 ng / mL, 500 ng / mL), and an IgG humanized antibody treatment group (50 ng / mL, 500 ng / mL). The terminal hair was treated in each group, and then cultured in an incubator at 37°C for 2 days.
[0062] As shown in FIGS. 6 and 7, the results of the mouse hair follicle culture experiment demonstrated that treatment with the humanized antibody against CXCL12 of the present invention promoted the growth of all hair follicles.
[0063] Therefore, it was confirmed that the humanized antibody against CXCL12 of the present invention promotes the growth of hair follicles by suppressing CXCL12, and has an excellent hair growth effect. EXAMPLES
[0064] Confirmation of hair growth promoting effect by treatment with humanized antibody against CXCL12 in a mouse anagen induction model The hair growth promoting effect of the humanized antibody against CXCL12 prepared in Example 4 was confirmed as follows.
[0065] The hair of 23 7-week-old male C3H / HeN mice was shortened using a hair removal machine, and the remaining hair was completely removed using a hair remover, after which the mice were allowed to acclimate for one day. The experiment was conducted in groups of 5 to 6 mice each. The groups were as follows: Group 1: Control group (IgG1, 50 μg / head), 5 animals Group 2: Chimeric antibody (50 μg / head) administration group, 6 animals Group 3: (#1) VH1-VL1 antibody (50 μg / head) administration group, 6 animals Group 4: (#3) VH1-VL3 antibody (50 μg / head) administration group, 6 animals Group 5: (#4) VH2-VL1 antibody (50 μg / head) administration group, 6 animals
[0066] Each group of mice was subcutaneously injected once into the back of the mouse (50 μg / head), and the degree of hair growth on the back of the mouse was monitored for 17 days after the injection of each antibody. After 17 days, the backs of the mice with hair growth were shaved with a razor, and the weight of the hair obtained was measured.
[0067] As shown in Figures 8 and 9, the hair growth promoting effect in mice was evaluated, and it was confirmed that treatment with the humanized antibody against CXCL12 of the present invention promoted hair growth.
[0068] Therefore, it was confirmed that the humanized antibody against CXCL12 of the present invention promotes hair growth by suppressing CXCL12, and has an excellent hair growth effect. EXAMPLES
[0069] Confirmation of hair growth promotion effect of humanized antibody against CXCL12 in an animal model of alopecia areata The hair growth promoting effect of the humanized antibody against CXCL12 prepared in Example 4 was confirmed as follows.
[0070] Eddy Hsi Chun Wang et al. conducted an experiment to establish an animal model of alopecia areata by transplanting skin-draining lymph node cells (LNC) from animals with alopecia areata (alopecia areata) into a 10-week-old C3H / HeJ animal model. The experiment was conducted in groups of three animals. The groups were as follows: Group 1: Control group (IgG1, 100μg / head), 3 animals Group 2: VH1-VL3 antibody (100 μg / head) administration group, 3 animals
[0071] On the 1st and 10th days after the start of the experiment, each group of mice was subcutaneously injected twice into the abdominal skin (dosage 50 μg / head / time), and the hair loss sites were photographed over a period of 6 weeks to observe the hair growth condition of the mice's skin.
[0072] As shown in FIG. 10, the hair growth promoting effect was evaluated in an animal model of alopecia areata, and it was confirmed that treatment with the humanized antibody against CXCL12 of the present invention promoted hair growth.
[0073] Therefore, it was confirmed that the humanized antibody against CXCL12 of the present invention promotes hair growth and has excellent hair growth effects by suppressing CXCL12, and in particular has a therapeutic effect on alopecia areata.
Claims
1. a heavy chain variable region comprising a CDRH1 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:5, and a CDRL3 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:6; A monoclonal antibody that specifically binds to CXCL12.
2. a heavy chain variable region comprising a CDRH1 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:5, and a CDRL3 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:6; A monoclonal antibody that specifically binds to CXCL12 according to claim 1.
3. a heavy chain variable region comprising a CDRH1 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:5, and a CDRL3 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:6; A monoclonal antibody that specifically binds to CXCL12 according to claim 1.
4. a heavy chain variable region comprising a CDRH1 having the amino acid sequence of SEQ ID NO:1, a CDRH2 having the amino acid sequence of SEQ ID NO:2, and a CDRH3 having the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having the amino acid sequence of SEQ ID NO:4, a CDRL2 having the amino acid sequence of SEQ ID NO:5, and a CDRL3 having the amino acid sequence of SEQ ID NO:6; A monoclonal antibody that specifically binds to CXCL12 according to claim 1.
5. a heavy chain variable region comprising a CDRH1 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:5, and a CDRL3 having a sequence having 90% or more sequence identity with the amino acid sequence of SEQ ID NO:6; A humanized antibody that specifically binds to CXCL12.
6. a heavy chain variable region comprising a CDRH1 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:5, and a CDRL3 having a sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO:6; A humanized antibody that specifically binds to CXCL12 according to claim 5.
7. a heavy chain variable region comprising a CDRH1 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:1, a CDRH2 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:2, and a CDRH3 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:4, a CDRL2 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:5, and a CDRL3 having a sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO:6; A humanized antibody that specifically binds to CXCL12 according to claim 5.
8. a heavy chain variable region comprising a CDRH1 having the amino acid sequence of SEQ ID NO:1, a CDRH2 having the amino acid sequence of SEQ ID NO:2, and a CDRH3 having the amino acid sequence of SEQ ID NO:3; a light chain variable region comprising a CDRL1 having the amino acid sequence of SEQ ID NO:4, a CDRL2 having the amino acid sequence of SEQ ID NO:5, and a CDRL3 having the amino acid sequence of SEQ ID NO:6; A humanized antibody that specifically binds to CXCL12 according to claim 5.
9. A heavy chain variable region comprising a sequence having 90% or more sequence identity with any of the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9; A light chain variable region comprising a sequence having 90% or more sequence homology with any one of the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12, A humanized antibody that specifically binds to CXCL12.
10. A heavy chain variable region comprising a sequence having 95% or more sequence identity with any of the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9; A light chain variable region comprising a sequence having 95% or more sequence homology with any one of the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12, A humanized antibody that specifically binds to CXCL12 according to claim 9.
11. A heavy chain variable region comprising a sequence having 99% or more sequence identity with any of the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9; A light chain variable region comprising a sequence having 99% or more sequence homology with any one of the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12, A humanized antibody that specifically binds to CXCL12 according to claim 9.
12. A heavy chain variable region comprising any one of the amino acid sequences of SEQ ID NO: 7 to SEQ ID NO: 9; and a light chain variable region comprising any one of the amino acid sequences of SEQ ID NO: 10 to SEQ ID NO: 12; A humanized antibody that specifically binds to CXCL12 according to claim 9.
13. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
10. A humanized antibody that specifically binds to CXCL12 according to claim 9.
14. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
11. A humanized antibody that specifically binds to CXCL12 according to claim 9.
15. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
12. A humanized antibody that specifically binds to CXCL12 according to claim 9.
16. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
10. A humanized antibody that specifically binds to CXCL12 according to claim 9.
17. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
11. A humanized antibody that specifically binds to CXCL12 according to claim 9.
18. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
12. A humanized antibody that specifically binds to CXCL12 according to claim 9.
19. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
10. A humanized antibody that specifically binds to CXCL12 according to claim 9.
20. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
11. A humanized antibody that specifically binds to CXCL12 according to claim 9.
21. A heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9; and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
12. A humanized antibody that specifically binds to CXCL12 according to claim 9.
22. A pharmaceutical composition for preventing or treating hair loss, comprising the antibody according to any one of claims 1 to 21.
23. The hair loss is selected from the group consisting of alopecia areata, hereditary androgenic alopecia, telogen effluvium, traumatic alopecia, trichotillomania, pressure induced alopecia, anagen effluvium, pityriasis alopecia, syphilitic alopecia, seborrheic alopecia, symptomatic alopecia, cicatricial alopecia, congenital alopecia, and hair loss due to side effects of medication; The pharmaceutical composition for preventing or treating hair loss according to claim 22.
24. The hair loss caused by the side effect of a drug is hair loss caused by a drug selected from the group consisting of an anticancer drug, an anticoagulant, an antidepressant, and a hormone drug. A pharmaceutical composition for preventing or treating hair loss according to claim 23.
25. The anticancer agent is an anticancer agent for treating a cancer selected from the group consisting of melanoma, epithelial cancer, breast cancer, cervical cancer, solid cancer, urothelial cell cancer, non-small cell lung cancer, pancreatic adenocarcinoma, renal cancer, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer and gastrointestinal cancer. A pharmaceutical composition for preventing or treating hair loss according to claim 24.
26. A polynucleotide encoding the antibody of any one of claims 1 to 21.
27. A vector comprising the polynucleotide of claim 26.
Citation Information
Patent Citations
Anti-CXCL12 antibody molecule and its use
JP2018505144A
